Replies to post #417013 on NorthWest Biotherapeutics Inc (NWBO)

[sukus]

Good luck to you Dan and all longs.

[ilovetech]

Dan88, I learned my lesson with Amarin. Amarin enjoyed a standing ovation in a room filled with 2000 Cardiologists at the AHA when TLD was released. BUT, management was "ill prepared" to defend the SP against one hit piece from AF and another from Forbs, which featured a KOL, who said he suspected that the placebo used for control was likely not inert causing control to do poorly. So we went from $2.37 to $26 to $14.

To make matters worse, a high priced patent law firm blew defending Amarin's patents and we languish in the $4's today.

People should make no mistake, the market doesn't play nice just because it's the stock you own. Moreover, we've already felt AF's impact on NWBO, and he's still committed to seeing it's demise.

So let's not keep banging away at the notion that positive TLD will block any such market turning attacks. I can accuse the market for being all kinds of things, but it won't help me recover when I'm on the receiving end. Given that experience, I'd much rather see NWBO moving expeditiously on all required actions under it's control, and hopefully build layers of protection, which I've learned is invaluable in biotech.

ILT

[HappyLibrarian]

With sagging market for a stock like NWBO, I am always a buyer. Instead, I have bought with borrowed money recently.

God permits, I am current on loan.

This is exactly why bringing the history up of rug pulls and stringing along is crucial so that if people make a mistake it will be a well informed mistake.

I have been around long enough to remember investors boasting about taking out a loan to buy more shares back when this was somewhere between $4.00 and $10.00 and news was ostensibly imminent.

Pretty much anything foreseeable that could happen with NWBO post-TLD is not going to make people like that get gains commensurate with the years of misery.

I can only hope those really weren't shareholders back then and it is sad to see another generation of investors falling into the same trap.